• Home
  • Contact
  • EnglishEnglish
    • DeutschDeutsch
Prof. Marcus Maurer
  • Personal Background
  • Publications
  • Research
Select Page
The icatibant outcome survey: treatment of laryngeal angioedema attacks

The icatibant outcome survey: treatment of laryngeal angioedema attacks

by mm-red | Jul 30, 2020

Objective: To characterize the management and outcomes of life-threatening laryngeal attacks of hereditary angioedema (HAE) treated with icatibant in the observational Icatibant Outcome Survey (NCT01034969) registry. Methods: This retrospective analysis was based on...
The icatibant outcome survey: treatment of laryngeal angioedema attacks

Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the icatibant outcome survey

by mm-red | Jul 30, 2020

Icatibant is used to treat acute hereditary angioedema with C1 inhibitordeficiency types I/II (C1-INH-HAE types I/II) and has shown promise inangioedema due to acquired C1 inhibitor deficiency (C1-INH-AAE). Datafrom the Icatibant Outcome Survey (IOS) were analysed to...
The icatibant outcome survey: treatment of laryngeal angioedema attacks

Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice

by mm-red | Jul 30, 2020

The Icatibant Outcome Survey (IOS) is an observational study monitoring safetyand effectiveness of icatibant in the real-world setting. We analyzed safety datafrom 3025 icatibant-treated attacks in 557 patients (enrolled between July 2009and February 2015). Icatibant...
The icatibant outcome survey: treatment of laryngeal angioedema attacks

Analysis of characteristics associated with reinjection of icatibant: Results from the Icatibant Outcome Survey

by mm-red | Jul 29, 2020

The icatibant outcome survey: treatment of laryngeal angioedema attacks

Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals

by mm-red | Jul 29, 2020

Background: Icatibant, a selective bradykinin B2 receptor antagonist for the treatment of acute hereditary angio-oedema (HAE) attacks in adults, can be administered by health care professionals (HCPs) or self-administered. This analysis compared characteristics and...
« Older Entries

Recent Comments

    Archives

    Categories

    • No categories

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • Privacy Policy
    • Imprint
    • Cookie Policy (EU)
    © 2020 Marcus Maurer
    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage vendors Read more about these purposes
    View preferences
    {title} {title} {title}